Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mintaka: RO7268489 + Ocrelizumab in Progressive Multiple Sclerosis
NCT07282574Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of RO7268489 in multiple sclerosis (MS), sponsored by Roche. Started Mar 2026; status: recruiting.
02
Drugs
RO7268489
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07282574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282574.